Fast Takes
Get ahead with this short-form webinar series focused on the next phase of pharma’s digital transformation.
Get our latest webinar insights in just three minutes:
Fast Take #1:
Patient Support, Reimagined
See how digital is accelerating patient support solutions while lessening the burden on care support teams.
Fast Take #2:
Patient Engagement, Personalized
Watch how digital solutions allow pharma to deliver personalized ‘white-glove’ patient journeys at scale.
Fast Take #3:
Enterprise Solutions, at Scale
How digital technology centralizes elements of patient support portfolio-wide without sacrificing brand identity.
Fast Take #4
Economic Impact, Proven
See the multi-million dollar ROI for pharma when digital improves adherence, persistence, efficiencies and more.
Fast Take #1: Patient Support Delivery Reimagined (3 minutes)
What to look for when implementing technology into existing model of support, in three minutes.
Fast Take #2: Patient Engagement, Personalized (3 minutes)
Take three minutes to see how digital solutions allow pharma to deliver personalized ‘white-glove’ patient journeys at scale.
Fast Take #3: Enterprise Solutions at Scale (3 minutes)
How digital technology centralizes elements of patient support portfolio-wide without sacrificing brand identity.
See the multi-million dollar ROI for pharma when digital improves adherence, persistence, efficiencies and more.
Digital Drug Companion
Medication Engagement Platform
Patients receive complete treatment management through a combination of advanced technology and expert knowledge. Connect patients with an innovative digital platform that drives medication engagement, integrates human support and delivers a holistic care experience.
Download Medisafe:
Latest From Medisafe
Transforming Pharma Outcomes: Boosting Adherence & Persistence
Summary This case study examines the unmet needs in treatment adherence and persistence among patients with psoriasis, Crohn’s disease, and ulcerative colitis. Despite advances in biologic therapies, real-world evidence indicates nonadherence rates of up to 50% in psoriasis and 65% in inflammatory bowel disease, driving suboptimal outcomes and increased costs (Smith et al., 2021; Nguyen et al., 2019). Pharmaceutical companies face challenges in maintaining…